Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The technique draws on personal experience with gene augmentation therapy by subretinal injection in patients with choroideremia, RPE65 mutation-associated retinal dystrophy, and X-linked retinitis pigmentosa. Only 2 surgeons initially performed RPE65 gene therapy in the Phase 3 clinical trial leading to drug approval in the United States and the European Union.1 As new surgeons begin to use the commercially available product voretigene neparvovec-rzyl for RPE65 mutation–related inherited retinal dystrophy (IRD) or to participate in clinical trials, there is a need for education in best practices for subretinal injection. Clinical trials are currently listed on clinicaltrials.gov for choroideremia,2–5 X-linked retinitis pigmentosa (RPGR genotype), autosomal recessive retinitis pigmentosa (MERTK genotype), achromatopsia (CNGA3 and CNGB3), Stargardt disease (ABCA4), Leber congenital amaurosis (CEP290), and Usher syndrome type 1B (MY07A), with several additional subretinal gene therapies in the pipeline. There are few options with currently available technology for delivery of gene therapy for IRD other than subretinal injection. Intravitreal injection of gene therapy is simpler to perform but is predicted to be useful only for optic nerve or retinal diseases affecting primarily the retinal nerve fiber layer, ganglion cell layers, and inner retinal layers (e.g., Leber hereditary optic neuropathy and X-linked retinoschisis RS1) due to barriers presented by the internal limiting membrane and the retinal tissue.6,7 Microcatheters advanced into suprachoroidal space of rabbits achieved transfection with adeno-associated virus 2 (AAV2) vector as demonstrated by GFAP expression8; however, there is concern that therapy delivered to the suprachoroidal space would be more difficult to target, require higher doses, be more likely to disseminate to unwanted systemic sites, or fail to penetrate outer blood retinal barrier at the level of the retinal pigment epithelium and Bruch membrane. Therefore, subretinal injection is likely to remain the procedure of choice for the near future. Technological innovations may facilitate surgical delivery of vector to the subretinal space.9–12 Although previous publications discuss surgical technique for gene therapy surgery, they do not provide a complete, surgeon-oriented surgical plan that is easy to follow in the operating room. The surgeon's manual for administration of voretigene neparvovec-rzyl intentionally gives general instructions with few details to allow for surgical discretion. The current protocol may help experienced vitreoretinal surgeons new to gene therapy adapt their own procedures and operating room setting to facilitate safe and efficient surgery. Surgical Protocol Our methods of subretinal injection were refined during multiple surgeries at Bascom Palmer Eye Institute involving patients enrolled in Phase II to III clinical trials, but also patients treated with commercial products. Many steps are routine best practice procedures for vitreoretinal surgery adapted to a comprehensive plan for gene therapy surgery. The interventions described here were approved by the Human Subjects Research Office of the University of Miami when they involved patients enrolled in clinical trials. All patients signed standard consents for surgery as required by our hospital. Patient Selection and Preparation Select candidates by phenotype. Use CLIA-certified genetic testing to confirm the pathogenic genetic variant. Document retinal function with visual acuity, visual fields, and electrophysiology; retinal anatomy with fundus photography, optical coherence tomography (OCT), and autofluorescence. Use microperimetry to assess the favored fixation point. Obtain informed consent emphasizing risks of subretinal surgery including blindness, decreased vision, scarring, disease progression, injury to surrounding structures, inflammation, macular hole, and retinal detachment. Gene therapy surgery now may limit access to future clinical trials. Consider pretreatment with oral corticosteroids at up to 1 mg/kg for 3 days with postoperative taper. Doses higher than 60 to 80 mg daily may increase the risk of systemic complications. Vector Preparation Order gene vector product with sufficient lead-time for surgery. Coordinate time of surgery with vector prep time to ensure injection is within the viable use period. Have pharmacists prepare the vector using sterile protective gear in a negative pressure room and biohazard hood or as specified by protocol. Inspect vector for signs of contamination and verify that it is the intended product for the patient. Note expiration time. Preparation for Surgery Supplemental Digital Content 1 (see Table, https://links.lww.com/IAE/B27) lists commonly used instruments and supplies. Review photographs. Assess target zone and proposed injection sites. Plan the injection site(s) to cover the target zone without overstretching the retina or exceeding the allowed volume
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, various forms of RP exhibit relatively normal adhesion be tween the degenerate retina and the RPE (Davis et al., 2019; Chan et al., 2020); therefore, one-step injection at low pressures may be sufficient for bleb induction.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Davis et al., 2019
Citations
Cites
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Self-citationGene Therapy for Leber Hereditary Optic Neuropathy
Feuer, W. J., Schiffman, J. C., Davis, J. L., Porciatti, V., Gonzalez, P., Koilkonda, R. D., Yuan, H., Lalwani, A., Lam, B. L., & Guy, J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.025 · Cited by 230
Self-citationVisual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Self-citationTechnique of retinal gene therapy: delivery of viral vector into the subretinal space
Xue, K., Groppe, M., Salvetti, A. P., & MacLaren, R. E. (2017) · Eye · doi:10.1038/eye.2017.158 · Cited by 191
Self-citationBeneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0185-5 · Cited by 185
Self-citationTwo-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience
Dimopoulos, I. S., Hoang, S. C., Radziwon, A., Binczyk, N. M., Seabra, M. C., MacLaren, R. E., Somani, R., Tennant, M. T. S., & MacDonald, I. M. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.06.011 · Cited by 175
Self-citationChoroideremia gene therapy phase 2 clinical trial: 24-month results
Lam, B. L., Davis, J. L., Gregori, N. Z., MacLaren, R. E., Girach, A., Verriotto, J. D., Rodriguez, B., Rosa, P. R., Zhang, X., & Feuer, W. J. (2019) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.09.012 · Cited by 161
Self-citationRetinal gene therapy: surgical vector delivery in the translation to clinical trials
Ochakovski, G. A., Bartz-Schmidt, K. U., & Fischer, M. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00174 · Cited by 110
Robotic-assisted surgery in ophthalmology
de Smet, M. D., Naus, G. J. L., Faridpooya, K., & Mura, M. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000476 · Cited by 83
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“The creation of the subretinal bleb with a microneedle (typically a 38- to 41-gauge, Teflon-tipped, either extendable or nonextendable, cannula that is placed through a pars plana trocar) is a challenging and critical step in the procedure.(98) The needle-penetration step has a narrow margin of error: excessively deep…”
BackgroundClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
“It has been stated that there are no alternative methods to deliver vector-gene to the outer retina (Davis et al., 2019); without further research and a detailed understanding of”
InfluentialGene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
A Magnetically Navigated Microcannula for Subretinal Injections
Charreyron, S., Boehler, Q., Danun, A. N., Mesot, A., Becker, M. D., & Nelson, B. J. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.2996013 · Cited by 89
Metadata
- Authors
- Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L.
- Affiliations
- University of Miami (US)
- University of Oxford (GB)
- Corresponding author
- Davis, Janet L.
- Gregori, Ninel Z.
- Lam, Byron L.
- Venue
- Retina
- Published
- 2019-10
- Volume
- 39
- Issue
- 1
- Pages
- S2-S8
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2962807939
- Cited by
- 72
- References
- 19
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 9 · 2023: 13 · 2022: 3 · 2021: 17 · 2020: 10 · 2019: 1
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Retina (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- subretinal gene therapy, subretinal injection, surgical technique, inherited retinal degeneration, choroideremia, X-linked retinitis pigmentosa, adeno-associated virus vectors, suprachoroidal injection, surgical planning, retinal pigment epithelium
- MeSH terms
- Humans, Retina, Retinal Degeneration, Ophthalmologic Surgical Procedures, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. https://app.cochat.ai/papers/10.1097/iae.0000000000002609
- The paper
- Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019). Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. Retina. https://doi.org/10.1097/iae.0000000000002609
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.